Revance Therapeutics (RVNC) Reports Q2 Loss of $0.90/Share
Tweet
Share
E-mailGet Alerts RVNC Hot Sheet
Join SI Premium – FREE
Revance Therapeutics (NASDAQ: RVNC) reported Q2 EPS of ($0.90), versus ($0.88) reported last year.
For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- CMS targets 15% Medicare lab fee cuts, putting DGX and LH revenue at risk
- Super Micro Computer rises on AI server market optimism
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
